Active, not recruitingPhase 3NCT05799287

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: RemeGen Co., Ltd.
Principal Investigator: Jicheng Lv, M.D.
Peking University First Hospital
Intervention: Telitacicept(biological)
Enrollment: 318 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2026

Study locations (30)

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality, China
Beijing Hospital, Beijing, Beijing Municipality, China
Beijing Tsinghua Changgung Hospital, Beijing, Beijing Municipality, China
Peking University First Hospital, Beijing, Beijing Municipality, China
Peking University People's Hospital, Beijing, Beijing Municipality, China
Peking University Shougang Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Army Medical University, Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
Gansu Provincial Hospital, Lanzhou, Gansu, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05799287 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials